Yantai Dongcheng Pharmaceutical Co Ltd (SHE:002675) — Market Cap & Net Worth
Market Cap & Net Worth: Yantai Dongcheng Pharmaceutical Co Ltd (002675)
Yantai Dongcheng Pharmaceutical Co Ltd (SHE:002675) has a market capitalization of $1.52 Billion (CN¥10.37 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #7219 globally and #1534 in its home market, demonstrating a -0.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yantai Dongcheng Pharmaceutical Co Ltd's stock price CN¥12.58 by its total outstanding shares 824595705 (824.60 Million). Also see Yantai Dongcheng Pharmaceutical Co Ltd balance sheet assets for a full breakdown of the balance sheet.
Yantai Dongcheng Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Yantai Dongcheng Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.10 Billion to $1.52 Billion (-1.00% CAGR). Also see Yantai Dongcheng Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Yantai Dongcheng Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yantai Dongcheng Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Yantai Dongcheng Pharmaceutical Co Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.61x
Yantai Dongcheng Pharmaceutical Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.47x
Yantai Dongcheng Pharmaceutical Co Ltd's market cap is 8.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.61 Billion | $1.16 Billion | $130.95 Million | 1.39x | 12.31x |
| 2017 | $1.33 Billion | $1.60 Billion | $172.63 Million | 0.84x | 7.72x |
| 2018 | $891.93 Million | $2.33 Billion | $280.43 Million | 0.38x | 3.18x |
| 2019 | $1.83 Billion | $2.99 Billion | $154.71 Million | 0.61x | 11.85x |
| 2020 | $2.30 Billion | $3.42 Billion | $417.77 Million | 0.67x | 5.50x |
| 2021 | $1.84 Billion | $3.91 Billion | $151.56 Million | 0.47x | 12.16x |
| 2022 | $1.96 Billion | $3.58 Billion | $307.29 Million | 0.55x | 6.37x |
| 2023 | $2.19 Billion | $3.28 Billion | $209.74 Million | 0.67x | 10.44x |
| 2024 | $1.47 Billion | $2.87 Billion | $183.83 Million | 0.51x | 8.02x |
| 2025 | $1.66 Billion | $2.72 Billion | $195.63 Million | 0.61x | 8.47x |
Competitor Companies of 002675 by Market Capitalization
Companies near Yantai Dongcheng Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Yantai Dongcheng Pharmaceutical Co Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Yantai Dongcheng Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Yantai Dongcheng Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yantai Dongcheng Pharmaceutical Co Ltd's market cap moved from $2.10 Billion to $ 1.52 Billion, with a yearly change of -1.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.52 Billion | -8.44% |
| 2025 | CN¥1.66 Billion | +12.44% |
| 2024 | CN¥1.47 Billion | -32.68% |
| 2023 | CN¥2.19 Billion | +11.87% |
| 2022 | CN¥1.96 Billion | +6.26% |
| 2021 | CN¥1.84 Billion | -19.77% |
| 2020 | CN¥2.30 Billion | +25.25% |
| 2019 | CN¥1.83 Billion | +105.58% |
| 2018 | CN¥891.93 Million | -33.10% |
| 2017 | CN¥1.33 Billion | -17.32% |
| 2016 | CN¥1.61 Billion | -23.20% |
| 2015 | CN¥2.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Yantai Dongcheng Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.52 Billion USD |
| MoneyControl | $1.52 Billion USD |
| MarketWatch | $1.52 Billion USD |
| marketcap.company | $1.52 Billion USD |
| Reuters | $1.52 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti… Read more